Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Biomimetic Surface Engineering of Biomaterials by Using Recombinant Mussel Adhesive Proteins

(2018) Yun Kee Jo et al.   Advanced Materials Interfaces

Sprayable Adhesive Nanotherapeutics: Mussel-Protein-Based Nanoparticles for Highly Efficient Locoregional Cancer Therapy

(2018) Yeonsu Jeong et al.   ACS Nano

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

(2018) Qian Chen et al.   Nature Nanotechnology

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors

(2016) Yanqi Ye et al.   ACS Nano

Switch of Surface Adhesion to Cohesion by Dopa-Fe3+ Complexation, in Response to Microenvironment at the Mussel Plaque/Substrate Interface

(2016) Byeongseon Yang et al.   CHEMISTRY OF MATERIALS

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody

(2016) Chao Wang et al.   NANO LETTERS

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Mussel adhesion-employed water-immiscible fluid bioadhesive for urinary fistula sealing

(2015) Hyo Jeong Kim et al.   BIOMATERIALS

Rapidly light-activated surgical protein glue inspired by mussel adhesion and insect structural crosslinking

(2015) Eun Young Jeon et al.   BIOMATERIALS

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

The STING pathway and the T cell-inflamed tumor microenvironment

(2015) Seng-Ryong Woo et al.   TRENDS IN IMMUNOLOGY

Nanomechanics of Cation-π Interactions in Aqueous Solution

(2013) Qingye Lu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

(2013) B. Kwong et al.   CANCER RESEARCH

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reinforced Multifunctionalized Nanofibrous Scaffolds Using Mussel Adhesive Proteins

(2011) Bum Jin Kim et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Mussel-Inspired Adhesives and Coatings

(2011) Bruce P. Lee et al.   Annual Review of Materials Research

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

(2011) Brandon Kwong et al.   BIOMATERIALS

Strong reversible Fe3+-mediated bridging between dopa-containing protein films in water

(2010) H. Zeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recent advances in the surface forces apparatus (SFA) technique

(2010) J Israelachvili et al.   REPORTS ON PROGRESS IN PHYSICS

Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy

(2009) Yuki Hori et al.   BIOMATERIALS

Development of bioadhesives from marine mussels

(2008) Hyung Joon Cha et al.   Biotechnology Journal

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

(2008) B. G. Molenkamp et al.   CLINICAL CANCER RESEARCH